BioPharma Resources

Drugs by condition

Drugs approved for plaque psoriasis

Brand-name prescription drugs and biologics whose FDA label lists plaque psoriasis as an approved use. Matched on the label phrases: "plaque psoriasis".

Last checked: Nov 19, 2026Source: FDA labels (openFDA), Drugs@FDAMethods & limitations

Brand-name drugs approved

62

Still marketed, NDA or BLA

Drug classes

14

Novel drugs

18

New molecular entities and new biologics

In development

28

Investigational drugs in Phase 2 or 3

Newest approvals

The most recently first-approved brand-name drugs for plaque psoriasis.

  • Icotyde (Icotrokinra Hydrochloride) · Janssen Biotech NovelPriority reviewMar 17, 2026
  • Otezla (Apremilast) · Amgen INC OrphanAug 29, 2025
  • Starjemza (Ustekinumab-Hmny) · Bio-Thera Solutions LTD May 22, 2025
  • Otulfi (Ustekinumab-Aauz) · Fresenius Kabi USA Apr 30, 2025
  • Pyzchiva (Ustekinumab-Ttwe) · Samsung Bioepis CO LTD Apr 30, 2025

All approved drugs for plaque psoriasis, by class

Every marketed NDA or BLA whose current FDA label names this condition in its Indications and Usage section, plus 36 generic labels. A drug can be approved for only part of a condition (one subtype or stage, or as add-on therapy), so check its label.

Tumor Necrosis Factor Blocker (10)

  • Cimzia Certolizumab Pegol · Ucb INC · 2008
  • Enbrel Etanercept · Immunex · 1998
  • Remicade Infliximab · Centocor INC · 1998
  • Yusimry Adalimumab-Aqvh · Emerge Bioscience Pte LTD · 2021
  • Avsola Infliximab-Axxq · Amgen INC · 2019
  • Hadlima Adalimumab-Bwwd · Samsung Bioepis CO LTD · 2019
  • Hyrimoz Adalimumab-Adaz · Sandoz INC · 2018
  • Renflexis Infliximab-Abda · Samsung Bioepis CO LTD · 2017
  • Amjevita Adalimumab-Atto · Amgen INC · 2016
  • Inflectra Infliximab-Dyyb · Celltrion INC · 2016

Interleukin-12 Antagonist (9)

  • Stelara Ustekinumab · Centocor Ortho Biotech INC · 2009
  • Starjemza Ustekinumab-Hmny · Bio-Thera Solutions LTD · 2025
  • Otulfi Ustekinumab-Aauz · Fresenius Kabi USA · 2025
  • Pyzchiva Ustekinumab-Ttwe · Samsung Bioepis CO LTD · 2025
  • Steqeyma Ustekinumab-Stba · Celltrion, Inc. · 2024
  • Pyzchiva Ustekinumab-Ttwe · Samsung Bioepis CO LTD · 2024
  • Wezlana Ustekinumab-Auub · Amgen INC · 2023
  • Wezlana Ustekinumab-Auub · Amgen INC · 2023
  • Stelara Ustekinumab · Janssen Biotech · 2016

Interleukin-23 Antagonist (4)

  • Skyrizi Risankizumab-Rzaa · Abbvie INC · 2019
  • Ilumya Tildrakizumab-Asmn · Sun Pharma Global · 2018
  • Tremfya Guselkumab · Janssen Biotech · 2017
  • Skyrizi Risankizumab-Rzaa · Abbvie INC · 2022

Phosphodiesterase 4 Inhibitor (4)

  • Otezla Apremilast · Amgen INC · 2014
  • Otezla Apremilast · Amgen INC · 2025
  • Zoryve Roflumilast · Arcutis · 2023
  • Zoryve Roflumilast · Arcutis · 2022

Vitamin D Analog (4)

  • Dovonex Calcipotriene · Leo Pharma As · 1993
  • Wynzora Betamethasone Dipropionate, Calcipotriene · Mc2 · 2020
  • Sorilux Calcipotriene · Mayne Pharma · 2010
  • Dovonex Calcipotriene · Leo Pharma As · 1996

Interleukin-17A Antagonist (3)

  • Taltz Ixekizumab · Eli Lilly and CO · 2016
  • Cosentyx Secukinumab · Novartis Pharms Corp · 2015
  • Cosentyx Secukinumab · Novartis Pharms Corp · 2023

Retinoid (3)

  • Tazorac Tazarotene · Chartwell Rx · 1997
  • Duobrii Halobetasol Propionate, Tazarotene · Bausch · 2019
  • Tazorac Tazarotene · Chartwell Rx · 2000

Calcineurin Inhibitor Immunosuppressant (2)

  • Neoral Cyclosporine · Novartis · 1995
  • Neoral Cyclosporine · Novartis · 1995

Tyrosine Kinase 2 Inhibitor (1)

  • Sotyktu Deucravacitinib · Bristol · 2022

Aryl Hydrocarbon Receptor Agonist (1)

  • Vtama Tapinarof · Organon LLC · 2022

Interleukin-17 Receptor A Antagonist (1)

  • Siliq Brodalumab · Valeant Luxembourg · 2017

Corticosteroid (1)

  • Topicort Desoximetasone · Sun Pharma Canada · 2013

Vitamin D3 Analog (1)

  • Vectical Calcitriol · Galderma Labs Lp · 2009

Class not listed in FDA's data (18)

  • Icotyde Icotrokinra Hydrochloride · Janssen Biotech · 2026
  • Bimzelx Bimekizumab-Bkzx · Ucb INC · 2023
  • Humira Adalimumab · Abbvie INC · 2002
  • Imuldosa Ustekinumab-Srlf · Accord Biopharma Inc. · 2024
  • Selarsdi Ustekinumab-Aekn · Alvotech USA INC · 2024
  • Simlandi Adalimumab-Ryvk · Alvotech USA INC · 2024
  • Idacio Adalimumab-Aacf · Fresenius Kabi USA · 2024
  • Yuflyma Adalimumab-Aaty · Celltrion · 2023
  • Hulio Adalimumab-Fkjp · Mylan Pharms INC · 2020
  • Abrilada Adalimumab-Afzb · Pfizer INC · 2019
  • Bryhali Halobetasol Propionate · Bausch · 2018
  • Impoyz Clobetasol Propionate · Primus Pharms · 2017
  • Cyltezo Adalimumab-Adbm · Boehringer Ingelheim · 2017
  • Sernivo Betamethasone Dipropionate · Primus Pharms · 2016
  • Ultravate Halobetasol Propionate · Lacer Pharma · 2015
  • Enstilar Betamethasone Dipropionate, Calcipotriene · Leo Pharma As · 2015
  • Taclonex Betamethasone Dipropionate, Calcipotriene, Calcipotriene Hydrate · Leo Pharma As · 2008
  • Taclonex Betamethasone Dipropionate, Calcipotriene · Leo Pharma As · 2006

Drugs in development for plaque psoriasis

Investigational drugs FDA has not approved, in active or recent industry-sponsored Phase 2 and 3 trials for this condition. Phase 3 first.

Search the pipeline
  • ZasocitinibTAK- 279, NDI-034858Phase 317 trials

    Takeda · Plaque Psoriasis, Psoriatic Arthritis, Crohn's Disease

  • TLL-018Phase 38 trials

    Hangzhou Highlightll Pharmaceutical Co., Ltd · Chronic Spontaneous Urticaria (CSU), Rheumatoid Arthritis, Chronic Spontaneous Urticaria

  • EnvudeucitinibPhase 34 trials

    Alumis Inc · Plaque Psoriasis, SLE

  • ICP-332Phase 34 trials

    Beijing InnoCare Pharma Tech Co., Ltd. · Non Segmental Vitiligo, Chronic Spontaneous Urticaria (CSU), Atopic Dermatitis

  • TQH3906Phase 34 trials

    Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd. · Psoriasis, Systemic Lupus Erythematosus, Psoriatic Arthritis

  • ICP-488Phase 33 trials

    Beijing InnoCare Pharma Tech Co., Ltd. · Plaque Psoriasis Patients, Primary Sjögren's Syndrome, Cutaneous Lupus Erythematosus (CLE)

  • SHR-1314Phase 33 trials

    Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Active Non-radiographic Axial Spondyloarthritis, Children and Adolescents Aged 6 to 18 With Moderate-to-Severe Plaque Psoriasis, Psoriatic Arthritis

  • CMS-D001Phase 32 trials

    Dermavon Holdings Limited · Moderate to Severe Plaque Psoriasis, Moderate to Severe Atopic Dermatitis

  • HS-20137QX004NPhase 32 trials

    Hansoh BioMedical R&D Company · Moderate-to-severe Plaque Psoriasis

  • NetakimabPhase 32 trials

    Biocad · Plaque Psoriasis

  • PicankibartPhase 32 trials

    Innovent Biopharmaceutical Technology (Hangzhou) Co., LTD. · Psoriatic Arthritis, Plaque Psoriasis

  • piclidenosonPhase 32 trials

    Can-Fite BioPharma · Plaque Psoriasis, Lowe Syndrome

  • SYHX1901Phase 32 trials

    CSPC Ouyi Pharmaceutical Co., Ltd. · Moderate to Severe Plaque Psoriasis, Severe Alopecia Areata

  • WD-890Phase 32 trials

    Zhejiang Wenda Pharma Technology LTD. · Brief Description of Focus of Study, Moderate to Severe Plaque Psoriasis

  • Alumis Inc · Plaque Psoriasis, Psoriasis (PsO), Psoriasis

  • GNR-068Phase 31 trial

    AO GENERIUM · Plaque Psoriasis

  • Alumis Inc · Plaque Psoriasis, Psoriasis (PsO), Psoriasis

  • QL2106Phase 31 trial

    Qilu Pharmaceutical Co., Ltd. · Plaque Psoriasis

  • SHR-1139Phase 25 trials

    Guangdong Hengrui Pharmaceutical Co., Ltd · Moderate to Severe Plaque Psoriasis, Palmoplantar Pustulosis of Adults, Pyoderma Gangrenosum

  • ORKA-002Phase 23 trials

    Oruka Therapeutics, Inc. · Plaque Psoriasis, Hidradenitis Suppurativa (HS)

More on plaque psoriasis: recruiting trials · published research

Related in immunology and inflammation: Rheumatoid arthritis · Psoriatic arthritis · Atopic dermatitis (eczema) · Crohn's disease · Ulcerative colitis · Ankylosing spondylitis · Lupus (SLE) · Hidradenitis suppurativa · Chronic hives (urticaria) · Alopecia areata

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.